TheEdgeResearch
Home / Stocks / MYCOF

Noveris Health Sciences Inc. (MYCOF)

OTC Healthcare Medical - Pharmaceuticals
$0.73 ▲ +0.00%
Market Cap
$42.7M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
-5.44
52-Wk Range
0.029-2.04
CEO
Jason Birmingham
Country
CA
Currency
USD

Noveris Health Sciences Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.73, up 0.00% on the session, giving a market capitalisation of $42.7M. On trailing twelve-month figures it carries a trailing P/E of -70.00, a net margin of 0.0%. Its beta of -5.44 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-70.00
Price / Sales
0.00
Price / Book
-1.42
EV / EBITDA
-924.87
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-0.46
Current ratio
0.00
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
3
IPO date
2021-01-08
Headquarters
Vancouver, BC, CA
About Noveris Health Sciences Inc.

Noveris Health Sciences Inc. operates as a biotechnology firm dedicated to the investigation, pharmaceutical development, and clinical evaluation of psilocybin-based products. Co-founded by Parente Carman, Damon Michaels, and Robert Roscow on September 27, 2013, the company maintains its headquarters in Vancouver, Canada.

Comparable companies

Noveris Health Sciences Inc. is most often compared with the following Healthcare names:

BQSTBTCYCHHEGLABFLUFFFOASMYPTKFYQPTFFTELIFVPHIF
More research on MYCOF
MYCOF technical analysis MYCOF TheEdge Score Compare against peers
Open full interactive analysis & DCF →